Brainstorm Cell Therapeutics Культура компании

Mr. Chaim Lebovits has been the Chief Executive Officer of Brainstorm Cell Therapeutics Inc. since September 22, 2015 and as its President since July 3, 2007. Mr. Lebovits serves as the Chief Executive Officer and President at ACC International Holdings Ltd. He has been the President of Dominion Minerals Corp. since July 30, 2008. He is the Founder of Rialto Energy (C???te d'Ivoire) Limited (AKA C & L Natural Resources Limited). He has been at the forefront of investments into mining and natural resources in emerging markets, especially the African region, for a number of years. He is active in gold exploration activities in Africaand oil and gas exploration in Israel. He served as the Principal Executive Officer at Brainstorm Cell Therapeutics Inc. since August 1, 2013. Mr. Lebovits led and negotiated many successful transactions with and on behalf of various African governments and international mining businesses. He has been a Director of Dominion Minerals Corp., since July 30, 2008. He served as a Director of Shemen Oil And Gas Resources Ltd. Mr. Lebovits served as a Non-Executive Director of Azonto Petroleum Ltd (formerly, Rialto Energy Limited) from July 24, 2010 to April 5, 2012.

Dr. Ralph Z. Kern, MD, MHSc has been Chief Operating Officer and Chief Medical Officer of Brainstorm Cell Therapeutics Inc. since March 6, 2017. Dr. Kern's previous industry appointments include Head of Neuroscience Medical Unit at Novartis and Global Medical Director of Personalized Genetic Health at Genzyme Corporation. Dr. Kern is an influential leader, consensus builder and strategic advisor with expertise translating science into global solutions for patient care. He served as Senior Vice President and Head of Worldwide Medical at Biogen, where he was a powerful contributor to Biogen's reputation as a world leader in biopharmaceutical innovation. He helped define the company's therapeutic area and medical/scientific strategies for Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, Parkinson's, neuro-degeneration and hemophilia. From 2011 to 2014, Dr. Kern served as Vice President and Head of Neuroscience Medical Unit at Novartis, where he developed and directed strategy, budget and advanced medical-commercial governance model for neuroscience. His team executed the medical and strategic plan for Gilenya???, administered to more than 150,000 patients worldwide. From 2006 to 2011, Dr. Kern was Global Medical Director of Personalized Genetic Health at Genzyme Corporation (now Sanofi Genzyme) where he championed global medical affairs and medical and scientific activities for Fabry disease life cycle management. From 2003 to 2006, he was University Neurology Program Director at the University of Toronto, where he developed the curriculum for post-graduate education in neurology and neurology bioethics, defined and evaluated training requirements for students and faculty and directed all operations of neurology post-graduate academic programs. Previously, he was a Neurologist Consultant at Mount Sinai Hospital, where he played a central role in identifying and publishing the first scientific description of central nervous system complications from the West Nile Virus epidemic in 2003. From 1988 to 2001, he was Director, EMG, EEG and Evoked Potential Laboratory at The Credit Valley Hospital, where he served on the Medicine Executive Committee and facilitated principal-investigator clinical trials for headache, epilepsy and stroke. Dr. Kern studied in the undergraduate Neurophysiology program at McGill University, received a Doctor of Medicine from Queen's University, completed post-graduate studies in neurology and neurophysiology at McGill University and a Master of Health Sciences (MHSc in Health Administration) from the University of Toronto.

Mr. Uri Yablonka has been the Chief Business Officer and Executive Vice President of Brainstorm Cell Therapeutics Inc. since March 6, 2017 and served as its Chief Operating Officer since June 6, 2014. Mr. Yablonka has experience in business consulting and development and media experience. Prior to joining Brainstorm and its Subsidiary, Mr. Yablonka was Owner and served as General Manager of Uri Yablonka Ltd., since 2011. He also served as Vice President, Business Development at ACC International Holdings Ltd. since 2011. Prior to serving with ACC International Holdings, Mr. Yablonka was Senior Partner of PM-PR Media Consulting Ltd. From 2008 to 2011, He was Senior Partner at PM-PR Media Consulting Ltd., where he led public relations and strategy consulting for a wide range of governmental and private organizations. From 2002 to 2008, he served as a Correspondent at the Maariv Daily News Paper, including extensive service as a Diplomatic Correspondent. He has been a Director at Brainstorm Cell Therapeutics Inc. since June 6, 2014.

Dr. Irit Arbel, DSc has been an Executive Vice President of Research and Development at Online Disruptive Technologies, Inc. since July 30, 2012. Dr. Arbel serves as a National Sales Manager of Laboratoires Merck Sharp & Dohme-Chibret SNC. She is a Member of the RFB Investment House management team. Dr. Arbel has 15 years of management experience in the areas of cell therapy, medical devices and pharmaceuticals. She was the co-founder and Chairperson of several medical device companies including Real Aesthetics Inc and BRH Medical. Dr. Arbel served as the President of Brainstorm Cell Therapeutics Inc. (Former Name: Golden Hand Resources Inc.) from April 28, 2004 to November 8, 2004 and served its Principal Executive Officer and Principal Accounting Officer until November 8, 2004. Dr. Arbel founded Brainstorm Cell Therapeutics Inc and has been its Chairperson since April 2014. She served as the President and Chief Executive Officer of Pluristem Therapeutics, Inc. (formerly AI Software Inc.) from May 30, 2003 to June 10, 2004. Following years of research in the fields of Alzheimer disease, immunology and osteoporosis with numerous publications, She has a wealth of managerial experience through her position as Israeli Sales Manager of Merck, Sharp & Dohme Ltd. (MSD) from February 1998 to December 2002. From 1995 to 1997, Dr. Arbel served as the Head of research for Hadassa - Ein Karem Hospital in Jerusalem, Israel. Dr. Arbel specialized in the use of pharmaceuticals for neurology, ophthalmology and dermatology treatments. She has been a Director of Pluristem Therapeutics, Inc. from May 30, 2003 to June 10, 2004. She is a Member of the Neurological Association and American Society of Hematology. Dr. Arbel also holds a Chemical Engineering degree from the Technion, Israel Institute of Technology. Dr. Arbel received a Bachelor's Degree in Biology from Hebrew University in 1983 and a Masters and PHD in Medical Sciences from Technion University in 1988. Dr. Arbel earned her Post Doctorate degree in 1997 in Neurobiology from Hadassah Hospital Neurological Department. She has a Doctor of Science (D.Sc.) in Neurology from The Technion Medical School.

Joe Petroziello serves as the VP of Scientific & Corporate Communications of Brainstorm Cell Therapeutics. Joe started at Brainstorm Cell Therapeutics in July of 2018. Joe currently resides in Greater New York City Area.

Ralph Kern serves as the EVP, Chief Operating Officer of Brainstorm Cell Therapeutics. Ralph started at Brainstorm Cell Therapeutics in March of 2017. Ralph currently resides in Greater Boston Area.

Arturo Araya serves as the Chief Commercial Officer of Brainstorm Cell Therapeutics. Arturo started at Brainstorm Cell Therapeutics in September of 2018. Arturo currently resides in Greater New York City Area.

Mary Turner serves as the Vice President of Patient Advocacy and Government Affairs of Brainstorm Cell Therapeutics. Mary currently resides in the Greater New York City Area.